BioSpace News Archive

According to Nova one advisor, the global Multiplex Detection Immunoassays market was valued at USD 1.8 billion in 2020 and it is expected to hit around USD 3.7 billion by 2030 with a CAGR of 9.7% during the forecast period 2022 to 2030.

According to the global Pharmaceutical Drug Delivery market size was estimated at USD 1,476.19 billion in 2021 and is expected to surpass around USD 2,047.36 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 3.7% during the forecast period 2022 to 2030.

According to Nova one advisor, the global Oral Transmucosal Drugs market was valued at USD 15.2 billion in 2021 and it is expected to hit around USD 24 billion by 2030 with a CAGR of 5.2% during the forecast period 2022 to 2030.

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock.

Evernow, a telehealth company dedicated to using science to transform and expand care for women in perimenopause and beyond, announces the presentation of its groundbreaking research this week at the North American Menopause Society’s (NAMS) annual clinical meeting in Atlanta, GA.

Confluent Medical Technologies, Inc. (“Confluent”) today announced that Matthew K. Eckl has been appointed as Chief Financial Officer (“CFO”) for the company, effective October 17, 2022.

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President, Global Marketing.

Beyond Air, Inc. (NASDAQ: XAIR) today announced positive safety, tolerability, and efficacy data from the LungFit GO pilot at-home study of patients with severe, treatment refractory, nontuberculous mycobacteria (NTM) lung disease.

Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, today announced that it will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022.